How Is Archer Aviation Advancing Toward Aircraft Certification?

Archer Aviation is continuing certification work on its Midnight aircraft, with progress in flight testing, system validation and regulatory engagement that could support commercial deliveries and customer deployments. The article also notes Archer is trading at 1.78x trailing price-to-book versus a 6.02x industry average, while the Zacks Consensus Estimate calls for 61.90% EPS decline in 2026 followed by 7.51% growth in 2027. Overall, the update is constructive but largely incremental, with certification progress remaining the key catalyst.

Analysis

Certification is the real binary for this group, but the market is likely underpricing how uneven the payoff curve is across ACHR, JOBY, and BETA. The near-term value inflection is less about “approval” in the abstract and more about which company can convert regulatory progress into de-risked customer commitments, because capital markets will reward evidence of delivery slots, not just test hours. ACHR appears to have the cleanest incremental catalyst path here, while smaller peers may lag on valuation multiple re-rating until they show similar execution density.

The second-order winner is the supplier and contract-manufacturing ecosystem, not just the air-taxi names. As certification confidence rises, avionics, battery systems, composite structures, and aerospace tooling vendors get a longer-duration backlog story before the aircraft OEMs themselves become cash generative. That matters because the OEM equity may remain funding-sensitive while suppliers can monetize the program ramp earlier through engineering services and pre-production commitments.

The biggest risk is timing slippage: any certification milestone that moves by quarters rather than months will likely compress multiples again, especially given these names trade more like duration assets than industrials. The current discount to book can look optically attractive, but book value is a weak anchor when the asset base is still pre-commercial and future dilution remains a live variable. In other words, the market may be pricing in a path to commercialization that is too smooth relative to the historical cadence of aerospace approvals.

Consensus is likely overemphasizing the headline progress and underestimating the probability that the first real monetization event is modest, not transformative. Early deliveries may validate the platform, but they are unlikely to justify a fundamental rerating unless there is evidence of scalable manufacturing, financing for working capital, and a credible path to unit economics. The better trade is to own the highest-quality execution story and avoid paying for the whole sector’s optionality when only one or two programs will likely clear the first commercialization hurdle on time.

Key Decisions for Investors

• Long ACHR vs. short JOBY or BETA on a 3-6 month horizon: ACHR should capture the highest beta to certification progress if the market continues rewarding incremental de-risking, while the pair reduces sector-wide regulatory risk.
• Buy ACHR on pullbacks only if it holds recent support into the next certification update; target a 15-25% upside re-rating on a clean milestone, with a tight 8-10% stop if timelines slip.
• Avoid initiating outright longs in BETA until there is clearer evidence of commercialization readiness; use it as a relative short against ACHR if investor attention rotates from progress narrative to execution quality.
• Consider a small call spread in ACHR expiring after the next expected regulatory checkpoint; the payoff is attractive if the market reprices certification odds, but theta decay limits downside if progress drags.
• Watch aerospace supply-chain names for a delayed beneficiary trade; if ACHR/JOBY gain traction, rotate into the most levered components and manufacturing vendors for a lower-duration way to express the commercialization theme.